Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674750 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
A Phase 2 study, sponsored by Curis.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02674750 is a Phase 2 study that has completed, run by Curis. The registered enrollment target is 70 participants.
The verdict
NCT02674750, a Phase 2 study, has completed, sponsored by Curis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Diffuse Large B-Cell Lymphoma (DLBCL).
Interventions
- DRUG CUDC-907
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02674750
The ClinicalTrials.gov registry entry for NCT02674750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CUDC-907 is the first listed.
NCT02674750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02674750 about?
NCT02674750 is a clinical study titled "Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations". This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Diffuse Large B-Cell Lymphoma (DLBCL).
What is the current status of trial NCT02674750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-07. Estimated completion is 2019-05-28.
What interventions are being tested in trial NCT02674750?
The interventions under investigation include: CUDC-907 (DRUG).
Who is sponsoring clinical trial NCT02674750?
This trial is sponsored by Curis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.